Denali Therapeutics Inc. DNLI Preferred Stock, Par or Stated Value Per Share
Preferred Stock, Par or Stated Value Per Share at other companies
Other financials
Where this comes from
Reported directly by Denali Therapeutics Inc. in its filing.
Tagged under the XBRL concept us-gaap:PreferredStockParOrStatedValuePerShare.
The official record: Denali Therapeutics Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Denali Therapeutics Inc.'s preferred stock, par or stated value per share.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Denali Therapeutics Inc.'s preferred stock, par or stated value per share?
- Denali Therapeutics Inc. (DNLI) reported preferred stock, par or stated value per share of $0.01 in Q1 2026.
- How has Denali Therapeutics Inc.'s preferred stock, par or stated value per share changed year-over-year?
- Denali Therapeutics Inc.'s preferred stock, par or stated value per share decreased by 0.0% year-over-year, from $0.01 to $0.01.
- What is the long-term trend for Denali Therapeutics Inc.'s preferred stock, par or stated value per share?
- Over 5 years (2020 to 2025), Denali Therapeutics Inc.'s preferred stock, par or stated value per share has grown at a 0.0% compound annual growth rate (CAGR), from $0.01 to $0.01.